Gregg Visit 1: Screening and Treatment of Chronic Hepatitis C in the Primary Care Setting

Title:

Gregg Visit 1: Screening and Treatment of Chronic Hepatitis C in the Primary Care Setting

Topic: Infectious Diseases
Relevant Terms: Hepatology, Hepatitis C, Cirrhosis, Liver Disease
Primary Audience: Primary care physicians; Nurse Practitioners; Physicians Assistants; and other healthcare professionals involved in the care of patients with chronic hepatitis C
Launch Date: 14-Nov-13
Credits: AMA PRA Category 1 Credit
1 ANCC contact hour
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Screening and Treatment of Chronic Hepatitis C: Navigating the Evolving Standard of Care

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Explain which patients should be screened for HCV infection based on current CDC and USPSTF recommendations
  2. Articulate increased confidence in the identification of HCV infection and recognize which patients will or will not likely benefit from use of DAA therapy
  3. List the benefits and the risks of existing and new therapeutic agents
  4. Recount the characteristics of patients for whom HCV treatment is generally accepted and those for whom the decision must be individualized or is contraindicated

    Faculty

    Robert Lowe, MD
    Director of Education, Gastroenterology
    Assistant Professor of Medicine
    Boston University School of Medicine
    Boston, MA
    Raymond T. Chung, MD
    Associate Professor of Medicine
    Harvard Medical School
    Chief of Hepatology
    Director of Liver Center
    Massachusetts General Hospital
    Boston, MA
    Lorraine Sanphy, RN
    CNE Course Advisor
    Staff Hepatology Nurse
    Boston Medical Center
    Boston, MA
    Practice Challenges Addressed
    This activity is designed to to initiate practice changes in the screening, diagnosis, and management of patients at risk of or diagnosed with HCV. Increasing the early diagnosis of HCV-infected persons will enable those patients to benefit from the availability of the latest treatments or choose to wait for upcoming therapies. New and emerging therapies for HCV are changing the standard of care, and clinicians must stay up to date with current data and clinical practice.This educational initiative will provide support and enable participating practitioners to enhance their knowledge and competency in the areas of patient care, medical knowledge, and practice-based learning and improvement.
     
    DISCLOSURE POLICY STATEMENT
    Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 
     
    DISCLAIMER
    THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.
     
    Faculty:
    Robert C. Lowe, MD
    CME Course Director
    Faculty has no relevant financial relationships with any commercial interest and DOES plan on discussing unlabeled/investigational uses of a commercial product.
     
    Raymond T. Chung, M.D.
    Faculty receives Grant/Research Support from Gilead, Mass Biologics, and Vertex. He is a consultant for AbbVie. He DOES plan on discussing unlabeled/investigational uses of a commercial product.
     
    Lorraine Sanphy, RN
    CNE Course Advisor
    Faculty has no relevant financial relationships with any commercial interest and does not plan on discussing unlabeled/investigational uses of a commercial product.
     
    Accreditation Planning
    Patti-Ann Collins, PhD, MSN, MBA, RN, Lead Nurse Planner, has no relevant financial relationships with any commercial interest.
    Jody Walker, MS, planner, has no relevant financial relationships with any commercial interest.
    Julie White, MS, planner, has no relevant financial relationships with any commercial interest.
     
    ACCREDITATION STATEMENTS
    Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Boston University School of Medicine designates this enduring educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

    CNE Contact Hours: 1.0 all of which are eligible for Pharmacotherapeutic credit.

    Nurses will receive contact hours after completion of an evaluation and claim for credit form.
     
    HOW TO RECEIVE CREDIT
    By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™, nurses are entitled to receive 1.0 CNE contact hours, all of which are pharmacology credit worthy. Statement of credit will be available to print from your user history page.
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the post-test and activity evaluation.
    • Physicians and nurses who successfully complete the post-test and evaluation will receive CME credits or CNE contact hours, respectively. You must score with a 70% or higher on the post-test to receive credit for this activity.
    • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
    Release Date: 11/14/2013
    Expiration Date: 11/13/2014
    Program Code: I.HEPCVISIT13
     
    For questions about CME, please contact cme@bu.edu or www.bu.edu/cme.
    To view Boston University's Privacy Policy, please see http://www.bumc.bu.edu/cme/policies/.
    To view RealCME's Privacy Policy, please see http://www.healthcourse.com/privacy/.

    COMMERCIAL SUPPORT
    This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
    This activity is supported by educational grant from AbbVie.
    This activity is supported by educational grant from Merck.
     


    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 18.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
    Safari 4.0+ for Mac OSX 10.5 and above
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above